# Trial to Evaluate the Safety, Tolerability and Immunogenicity of the Recombinant MVA BN® RSV Vaccine

> **NCT02419391** · PHASE1 · COMPLETED · sponsor: **Bavarian Nordic** · enrollment: 63 (actual)

## Conditions studied

- Respiratory Syncytial Virus Infections

## Interventions

- **BIOLOGICAL:** MVA BN RSV
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT02419391
- **Lead sponsor:** Bavarian Nordic
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-08
- **Primary completion:** 2015-12
- **Final completion:** 2016-05
- **Target enrollment:** 63 (ACTUAL)
- **Last updated:** 2016-08-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02419391

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02419391, "Trial to Evaluate the Safety, Tolerability and Immunogenicity of the Recombinant MVA BN® RSV Vaccine". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02419391. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*